Amneal Pharmaceuticals, Inc. (AMRX) FY2026 Q2 P&L / Income Statement

Amneal Pharmaceuticals, Inc. (AMRX) FY2026 Q2 P&L / Income Statement

Income statement for 2026-04-01 through 2026-06-30. View: Business segment. Revenue uses this breakdown; costs and expenses retain the consolidated categories.

Net revenue

796,197,000 US dollars

Cost of goods sold

461,689,000 US dollars

Gross profit

334,508,000 US dollars

Operating costs, net of other operating items (calculated)

204,739,000 US dollars

Operating income

129,769,000 US dollars

Total other expense, net

negative 58,779,000 US dollars

Income before income taxes

70,990,000 US dollars

Provision for income taxes

1,376,000 US dollars

Net income

69,614,000 US dollars

Affordable Medicines

489,913,000 US dollars

Specialty

149,295,000 US dollars

AvKARE

156,989,000 US dollars

Selling, general and administrative

148,722,000 US dollars

Research and development

39,017,000 US dollars

Intellectual property legal development expenses

2,087,000 US dollars

Restructuring and other charges

554,000 US dollars

Acquisition costs

7,600,000 US dollars

Other operating income

negative 1,298,000 US dollars

Charges (credit) related to legal matters, net

8,057,000 US dollars

Chart connections

• Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income.
• Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income.
• Of which attributable to Amneal Pharmaceuticals, Inc.: $57.66 M; to noncontrolling interests: $11.95 M.